Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Very strong margins and returns
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, underpriced
Target Price
The average target price of CPRX is 32 and suggests 34% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell